Gary Middleton

Professor of Medical Oncology

University of Birmingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

ORCID

Google Scholar

Academic Page

Articles (20)

The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

Article Link

Year:

2024

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Article Link

Year:

2023

Body composition and lung cancer-associated cachexia in TRACERx

Article Link

Year:

2023

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

Article Link

Year:

2023

Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Article Link

Year:

2023

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

Article Link

Year:

2023

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

Article Link

Year:

2023

The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review

Article Link

Year:

2023

Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (British Journal of Cancer, (2023), 128, 2, (161-164), 10.1038/s41416-022-02107-8)

Article Link

Year:

2023

Deep immune B and plasma cell repertoire in non-small cell lung cancer

Article Link

Year:

2023

TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer

Article Link

Year:

2022

A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications

Article Link

Year:

2022

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy

Article Link

Year:

2021

Using DNA sequencing data to quantify T cell fraction and therapy response

Article Link

Year:

2021

Towards personalized treatment of smoking-related lung cancers

Article Link

Year:

2021

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

Article Link

Year:

2021

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

Article Link

Year:

2021

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer

Article Link

Year:

2021

Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer

Article Link

Year:

2021

Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

Article Link

Year:

2020

Collaborators (23)

Ricky Thakrar

UNITED KINGDOM

Sarah Helen ORAM

University of Edinburgh

UNITED KINGDOM

Miriam Molina Arcas

The Francis Crick Institute

UNITED KINGDOM

Martin Forster

University College London

UNITED KINGDOM

Igor Vivanco

King’s College London

UNITED KINGDOM

Christian Ottensmeier

Professor of Immuno-Oncology

University of Liverpool

UNITED KINGDOM

Lennard Lee

Associate Professor

University of Oxford

UNITED KINGDOM

Csilla Varnai

University of Birmingham

UNITED KINGDOM

David Pearce

University College London

UNITED KINGDOM

Clare Weeden

The Francis Crick Institute

UNITED KINGDOM

Fiona Byrne

The Francis Crick Institute

UNITED KINGDOM

Michael Overduin

Professor

University of Alberta

CANADA

Lucy Cook

Honorary Senior Clinical Lecturer

Imperial College London

UNITED KINGDOM

Diana Johnson

University of Aberdeen

UNITED KINGDOM

Khalid AbdulJabbar

Institute of Cancer Research

UNITED KINGDOM

Mohammed Altohami

UNITED KINGDOM

Mark Middleton

University of Oxford

UNITED KINGDOM

Matthew Fittall

Honorary Associate Professor

University College London

UNITED KINGDOM

Andrea Sottoriva

Head

ITALY

peter parker

King’s College London

UNITED KINGDOM

Tim Robinson

University of Bristol

UNITED KINGDOM

Sarah Aitken

Assistant Professor

Yale University

UNITED STATES

Nicolai Birkbak

Aarhus University

DENMARK

Gary Middleton

Research Interests

Explore related searches

Contact this professor

Articles (20)

The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Body composition and lung cancer-associated cachexia in TRACERx

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review

Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care (British Journal of Cancer, (2023), 128, 2, (161-164), 10.1038/s41416-022-02107-8)

Deep immune B and plasma cell repertoire in non-small cell lung cancer

TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer

A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications

Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy

Using DNA sequencing data to quantify T cell fraction and therapy response

Towards personalized treatment of smoking-related lung cancers

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer

Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer

Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

Collaborators (23)

Ricky Thakrar

Sarah Helen ORAM

Miriam Molina Arcas

Martin Forster

Igor Vivanco

Christian Ottensmeier

Lennard Lee

Csilla Varnai

David Pearce

Clare Weeden

Fiona Byrne

Michael Overduin

Lucy Cook

Diana Johnson

Khalid AbdulJabbar

Mohammed Altohami

Mark Middleton

Matthew Fittall

Andrea Sottoriva

peter parker

Tim Robinson

Sarah Aitken

Nicolai Birkbak

How do I reach out?

Meet Kite AI